<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37604650</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>State of current management of the heightened risk for atherosclerotic cardiovascular events in an established cohort of patients with lupus erythematosus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000908</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2023-000908</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Patients with lupus erythematosus (LE) are at heightened risk for clinical events, chiefly heart attacks and strokes, from atherosclerotic cardiovascular disease (ASCVD). We recently proposed new guidelines to assess and manage ASCVD event risk specifically in LE. Here, we examined current cardiovascular management in light of these new recommendations.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We studied our entire UPenn Longitudinal Lupus Cohort of patients with cutaneous LE, without (CLE-only) or with (CLE+SLE) concurrent systemic LE, for whom we had full access to medical records (n=370, LE-ASCVD Study Cohort).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of our LE-ASCVD Study Cohort, 336 out of 370 (90.8%) had a designated primary-care physician. By the new guidelines, the most recent low-density lipoprotein (LDL) levels were above-goal for 249 out of 370 (67.3%). Two-hundred sixty-six (71.9%) had hypertension, which was undertreated or untreated in 198 out of 266 (74.4%). Of current smokers, 51 out of 63 (81.0%) had no documented smoking cessation counselling or referrals. Diabetes and triglyceridaemia were generally well managed. Of the cohort, 278 qualified for two widely used online estimators of ASCVD event risk in primary prevention: the ACC-ASCVD Risk Estimator Plus and QRisk3. We also stratified these 278 patients into our recently defined categories of ASCVD event risk in LE. These three methods for estimating ASCVD event risk showed clinically meaningful discordance for 169 out of 278 (60.8%). The documented rate of ASCVD events in the first 10 years after enrolment was 13.5% (95% CI 8.9%, 17.9%), similar between CLE-only and CLE+SLE, indicating an at-risk population despite the preponderance of women and an average age at enrolment of only 47 years.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients with CLE-only or CLE+SLE are undertreated compared with the new guidelines and, accordingly, they experience a significant burden of ASCVD events. Moreover, it is unclear how to accurately assess their future ASCVD event risk, except that it is substantial. Efforts are underway to improve ASCVD event risk estimation and guideline implementation in patients with lupus.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Megan</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8005-9111</Identifier><AffiliationInfo><Affiliation>Corporal Michael J. Crescenz Veterans' Administration Medical Center, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Rui</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-4151-7228</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werth</LastName><ForeName>Victoria P</ForeName><Initials>VP</Initials><Identifier Source="ORCID">0000-0003-3030-5369</Identifier><AffiliationInfo><Affiliation>Corporal Michael J. Crescenz Veterans' Administration Medical Center, Philadelphia, Pennsylvania, USA kjwilliams@temple.edu werth@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Kevin Jon</ForeName><Initials>KJ</Initials><Identifier Source="ORCID">0000-0002-0000-2159</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Sciences, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA kjwilliams@temple.edu werth@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="Y">Atherosclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atherosclerosis</Keyword><Keyword MajorTopicYN="N">Autoimmune Diseases</Keyword><Keyword MajorTopicYN="N">Cardiovascular Diseases</Keyword><Keyword MajorTopicYN="N">Lupus Erythematosus, Systemic</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>21</Day><Hour>21</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37604650</ArticleId><ArticleId IdType="pmc">PMC10445381</ArticleId><ArticleId IdType="doi">10.1136/lupus-2023-000908</ArticleId><ArticleId IdType="pii">10/2/e000908</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Keyes E, Grinnell M, Jacoby D, et al. . Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis. Int J Womens Dermatol 2021;7:560&#x2013;75. 10.1016/j.ijwd.2021.08.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijwd.2021.08.015</ArticleId><ArticleId IdType="pmc">PMC8721062</ArticleId><ArticleId IdType="pubmed">35024413</ArticleId></ArticleIdList></Reference><Reference><Citation>Akarsu S, Ozbagcivan O, Semiz F, et al. . High prevalence of metabolic syndrome in patients with discoid lupus erythematosus: a cross-sectional, case-control study. J Immunol Res 2017;2017:3972706. 10.1155/2017/3972706</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/3972706</ArticleId><ArticleId IdType="pmc">PMC5239982</ArticleId><ArticleId IdType="pubmed">28127570</ArticleId></ArticleIdList></Reference><Reference><Citation>Miot HA, Bartoli Miot LD, Haddad GR. Association between discoid lupus erythematosus and cigarette smoking. Dermatology 2005;211:118&#x2013;22. 10.1159/000086440</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000086440</ArticleId><ArticleId IdType="pubmed">16088157</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;ckle BC, Sepp NT. Smoking is highly associated with discoid lupus erythematosus and lupus erythematosus tumidus: analysis of 405 patients. Lupus 2015;24:669&#x2013;74. 10.1177/0961203314559630</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203314559630</ArticleId><ArticleId IdType="pubmed">25411260</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo LN, Nambudiri VE. Cutaneous lupus erythematosus and cardiovascular disease: current knowledge and insights into pathogenesis. Clin Rheumatol 2021;40:491&#x2013;9. 10.1007/s10067-020-05257-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05257-3</ArticleId><ArticleId IdType="pubmed">32623651</ArticleId></ArticleIdList></Reference><Reference><Citation>Urowitz MB, Bookman AA, Koehler BE, et al. . The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221&#x2013;5. 10.1016/0002-9343(76)90431-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9343(76)90431-9</ArticleId><ArticleId IdType="pubmed">1251849</ArticleId></ArticleIdList></Reference><Reference><Citation>Roman MJ, Shanker B-A, Davis A, et al. . Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399&#x2013;406. 10.1056/NEJMoa035471</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa035471</ArticleId><ArticleId IdType="pubmed">14681505</ArticleId></ArticleIdList></Reference><Reference><Citation>Asanuma Y, Oeser A, Shintani AK, et al. . Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2407&#x2013;15. 10.1056/NEJMoa035611</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa035611</ArticleId><ArticleId IdType="pubmed">14681506</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlucci PM, Purmalek MM, Dey AK, et al. . Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus. JCI Insight 2018;3:e99276. 10.1172/jci.insight.99276</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.99276</ArticleId><ArticleId IdType="pmc">PMC5931124</ArticleId><ArticleId IdType="pubmed">29669944</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med 2008;121:S3&#x2013;8. 10.1016/j.amjmed.2008.06.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2008.06.010</ArticleId><ArticleId IdType="pmc">PMC2581713</ArticleId><ArticleId IdType="pubmed">18926167</ArticleId></ArticleIdList></Reference><Reference><Citation>Shams-Eldin AN, Yafasova A, Faurschou M, et al. . Long-term risk of adverse cardiovascular outcomes associated with cutaneous lupus erythematosus: a nationwide cohort study. Clin Rheumatol 2022;41:3525&#x2013;36. 10.1007/s10067-022-06302-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06302-z</ArticleId><ArticleId IdType="pubmed">35907102</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995;15:551&#x2013;61. 10.1161/01.atv.15.5.551</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.atv.15.5.551</ArticleId><ArticleId IdType="pmc">PMC2924812</ArticleId><ArticleId IdType="pubmed">7749869</ArticleId></ArticleIdList></Reference><Reference><Citation>Bor&#xe9;n J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol 2016;27:473&#x2013;83. 10.1097/MOL.0000000000000330</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOL.0000000000000330</ArticleId><ArticleId IdType="pubmed">27472409</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott JR, Manzi S, Edmundowicz D. The role of preventive cardiology in systemic lupus erythematosus. Curr Rheumatol Rep 2007;9:125&#x2013;30. 10.1007/s11926-007-0006-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-007-0006-1</ArticleId><ArticleId IdType="pubmed">17502042</ArticleId></ArticleIdList></Reference><Reference><Citation>Munguia-Realpozo P, Mendoza-Pinto C, Sierra Benito C, et al. . Systemic lupus erythematosus and hypertension. Autoimmun Rev 2019;18:102371. 10.1016/j.autrev.2019.102371</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2019.102371</ArticleId><ArticleId IdType="pubmed">31415907</ArticleId></ArticleIdList></Reference><Reference><Citation>Masson W, Rossi E, Mora-Crespo LM, et al. . Cardiovascular risk stratification and appropriate use of statins in patients with systemic lupus erythematosus according to different strategies. Clin Rheumatol 2020;39:455&#x2013;62. 10.1007/s10067-019-04856-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-019-04856-z</ArticleId><ArticleId IdType="pubmed">31802350</ArticleId></ArticleIdList></Reference><Reference><Citation>Tselios K, Gladman DD, Taheri C, et al. . Factors associated with rapid progression to endstage kidney disease in lupus nephritis. J Rheumatol 2021;48:228&#x2013;31. 10.3899/jrheum.200161</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.200161</ArticleId><ArticleId IdType="pubmed">33259331</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghadam-Kia S, Chilek K, Gaines E, et al. . Cross-sectional analysis of a collaborative web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. Arch Dermatol 2009;145:255&#x2013;60. 10.1001/archdermatol.2008.594</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archdermatol.2008.594</ArticleId><ArticleId IdType="pmc">PMC2830744</ArticleId><ArticleId IdType="pubmed">19289753</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang AY, Piette EW, Foering KP, et al. . Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol 2011;147:1261&#x2013;7. 10.1001/archdermatol.2011.191</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archdermatol.2011.191</ArticleId><ArticleId IdType="pmc">PMC3282057</ArticleId><ArticleId IdType="pubmed">21768444</ArticleId></ArticleIdList></Reference><Reference><Citation>Piette EW, Foering KP, Chang AY, et al. . Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol 2012;148:317&#x2013;22. 10.1001/archdermatol.2011.342</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archdermatol.2011.342</ArticleId><ArticleId IdType="pmc">PMC3309110</ArticleId><ArticleId IdType="pubmed">22105815</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieczorek IT, Propert KJ, Okawa J, et al. . Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus. JAMA Dermatol 2014;150:291&#x2013;6. 10.1001/jamadermatol.2013.9026</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamadermatol.2013.9026</ArticleId><ArticleId IdType="pubmed">24477339</ArticleId></ArticleIdList></Reference><Reference><Citation>Keyes E, Jobanputra A, Feng R, et al. . Comparative responsiveness of cutaneous lupus erythematosus patients to methotrexate and mycophenolate mofetil: a cohort study. J Am Acad Dermatol 2022;87:447&#x2013;8. 10.1016/j.jaad.2021.09.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2021.09.017</ArticleId><ArticleId IdType="pmc">PMC10233728</ArticleId><ArticleId IdType="pubmed">34537250</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeidi M, Chen KL, Patel J, et al. . Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials. Lupus 2022;31:472&#x2013;81. 10.1177/09612033221084093</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221084093</ArticleId><ArticleId IdType="pmc">PMC8957607</ArticleId><ArticleId IdType="pubmed">35258358</ArticleId></ArticleIdList></Reference><Reference><Citation>American College of Cardiology . Available: https://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/</Citation></Reference><Reference><Citation>Arnett DK, Blumenthal RS, Albert MA, et al. . ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;140:e596&#x2013;646. 10.1161/CIR.0000000000000678</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000678</ArticleId><ArticleId IdType="pmc">PMC7734661</ArticleId><ArticleId IdType="pubmed">30879355</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippisley-Cox J, Coupland C, Brindle P. Development and validation of Qrisk3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 2017;357:j2099. 10.1136/bmj.j2099</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.j2099</ArticleId><ArticleId IdType="pmc">PMC5441081</ArticleId><ArticleId IdType="pubmed">28536104</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards N, Langford-Smith AWW, Parker BJ, et al. . QRISK3 improves detection of cardiovascular disease risk in patients with systemic lupus erythematosus. Lupus Sci Med 2018;5:e000272. 10.1136/lupus-2018-000272</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000272</ArticleId><ArticleId IdType="pmc">PMC6109811</ArticleId><ArticleId IdType="pubmed">30167314</ArticleId></ArticleIdList></Reference><Reference><Citation>QRisk3 . Available: https://qrisk.org/three/</Citation></Reference><Reference><Citation>Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457&#x2013;81. 10.1080/01621459.1958.10501452</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1958.10501452</ArticleId></ArticleIdList></Reference><Reference><Citation>Rich JT, Neely JG, Paniello RC, et al. . A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg 2010;143:331&#x2013;6. 10.1016/j.otohns.2010.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.otohns.2010.05.007</ArticleId><ArticleId IdType="pmc">PMC3932959</ArticleId><ArticleId IdType="pubmed">20723767</ArticleId></ArticleIdList></Reference><Reference><Citation>Uribe AG, Vil&#xe1; LM, McGwin G Jr, et al. . The Systemic Lupus Activity Measure-Revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a Modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol 2004;31:1934&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">15468356</ArticleId></ArticleIdList></Reference><Reference><Citation>Whelton PK, Carey RM, Aronow WS, et al. . 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71:e13&#x2013;115. 10.1161/HYP.0000000000000065</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYP.0000000000000065</ArticleId><ArticleId IdType="pubmed">29133356</ArticleId></ArticleIdList></Reference><Reference><Citation>The Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju S, et al. . Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016;388:776&#x2013;86. 10.1016/S0140-6736(16)30175-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)30175-1</ArticleId><ArticleId IdType="pmc">PMC4995441</ArticleId><ArticleId IdType="pubmed">27423262</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesselvig JH, Egeberg A, Kofoed K, et al. . Increased risk of depression in patients with cutaneous lupus erythematosus and systemic lupus erythematosus: a Danish nationwide cohort study. Br J Dermatol 2018;179:1095&#x2013;101. 10.1111/bjd.16831</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.16831</ArticleId><ArticleId IdType="pubmed">29885269</ArticleId></ArticleIdList></Reference><Reference><Citation>Sniderman AD. How, when, and why to use apolipoprotein B in clinical practice. Am J Cardiol 2002;90:48i&#x2013;54i. 10.1016/s0002-9149(02)02633-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9149(02)02633-4</ArticleId><ArticleId IdType="pubmed">12419480</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu MF, Xu KZ, Guo YG, et al. . Lipoprotein(a) and atherosclerotic cardiovascular disease: current understanding and future perspectives. Cardiovasc Drugs Ther 2019;33:739&#x2013;48. 10.1007/s10557-019-06906-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10557-019-06906-9</ArticleId><ArticleId IdType="pubmed">31655942</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MM, Watts GF. Contemporary perspectives on the genetics and clinical use of lipoprotein(a) in preventive cardiology. Curr Opin Cardiol 2021;36:272&#x2013;80. 10.1097/HCO.0000000000000842</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HCO.0000000000000842</ArticleId><ArticleId IdType="pubmed">33741767</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association . 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes&#x2014;2021. Diabetes Care 2021;44:S15&#x2013;33. 10.2337/dc21-S002</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc21-S002</ArticleId><ArticleId IdType="pubmed">33298413</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowler WC, Barrett-Connor E, Fowler SE, et al. . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393&#x2013;403. 10.1056/NEJMoa012512</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa012512</ArticleId><ArticleId IdType="pmc">PMC1370926</ArticleId><ArticleId IdType="pubmed">11832527</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan DM, DCCT/EDIC Research Group . The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study at 30 years: overview. Diabetes Care 2014;37:9&#x2013;16. 10.2337/dc13-2112</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc13-2112</ArticleId><ArticleId IdType="pmc">PMC3867999</ArticleId><ArticleId IdType="pubmed">24356592</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Prevention Program Research Group . Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care 2019;42:601&#x2013;8. 10.2337/dc18-1970</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc18-1970</ArticleId><ArticleId IdType="pmc">PMC6429636</ArticleId><ArticleId IdType="pubmed">30877090</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg RB, Orchard TJ, Crandall JP, et al. . Effects of long-term metformin and lifestyle interventions on cardiovascular events in the Diabetes Prevention Program and its Outcome Study. Circulation 2022;145:1632&#x2013;41. 10.1161/CIRCULATIONAHA.121.056756</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.056756</ArticleId><ArticleId IdType="pmc">PMC9179081</ArticleId><ArticleId IdType="pubmed">35603600</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht J, Taylor L, Berlin JA, et al. . The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005;125:889&#x2013;94. 10.1111/j.0022-202X.2005.23889.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0022-202X.2005.23889.x</ArticleId><ArticleId IdType="pmc">PMC3928016</ArticleId><ArticleId IdType="pubmed">16297185</ArticleId></ArticleIdList></Reference><Reference><Citation>Ming Wang TK, Chan N, Khayata M, et al. . Cardiovascular manifestations, imaging, and outcomes in systemic lupus erythematosus: an eight-year single center experience in the United States. Angiology 2022;73:877&#x2013;86. 10.1177/00033197221078056</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/00033197221078056</ArticleId><ArticleId IdType="pubmed">35238664</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiani AN, Post WS, Magder LS, et al. . Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. Rheumatology (Oxford) 2011;50:2071&#x2013;9. 10.1093/rheumatology/ker285</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ker285</ArticleId><ArticleId IdType="pmc">PMC3247795</ArticleId><ArticleId IdType="pubmed">21875880</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikdashi J, Nived O. Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research. Arthritis Res Ther 2015;17:183. 10.1186/s13075-015-0702-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-015-0702-6</ArticleId><ArticleId IdType="pmc">PMC4507322</ArticleId><ArticleId IdType="pubmed">26189728</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuklina EV, Yoon PW, Keenan NL. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006. JAMA 2009;302:2104&#x2013;10. 10.1001/jama.2009.1672</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2009.1672</ArticleId><ArticleId IdType="pubmed">19920234</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll MD, Kit BK, Lacher DA, et al. . Total and high-density lipoprotein cholesterol in adults: National Health and Nutrition Examination Survey, 2011-2012. NCHS Data Brief 2013;132:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24165064</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercado C, DeSimone AK, Odom E, et al. . Prevalence of cholesterol treatment eligibility and medication use among adults-United States, 2005-2012. MMWR Morb Mortal Wkly Rep 2015;64:1305&#x2013;11. 10.15585/mmwr.mm6447a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6447a1</ArticleId><ArticleId IdType="pubmed">26633047</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson AJ, O&#x2019;Brien EC, Kaltenbach LA, et al. . Use of lipid-, blood pressure-, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease. JAMA Netw Open 2022;5:e2148030. 10.1001/jamanetworkopen.2021.48030</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.48030</ArticleId><ArticleId IdType="pmc">PMC8855234</ArticleId><ArticleId IdType="pubmed">35175345</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone NJ. Treating severe hypercholesterolemia-if not now, when? JAMA Cardiol 2022;7:128&#x2013;9. 10.1001/jamacardio.2021.4987</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2021.4987</ArticleId><ArticleId IdType="pubmed">34780601</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon CP, de Lemos JA, Rosenson RS, et al. . Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol 2021;6:1&#x2013;9. 10.1001/jamacardio.2021.1810</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2021.1810</ArticleId><ArticleId IdType="pmc">PMC8209562</ArticleId><ArticleId IdType="pubmed">34132735</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon SS, Gu Q, Nwankwo T, et al. . Trends in blood pressure among adults with hypertension: United States, 2003 to 2012. Hypertension 2015;65:54&#x2013;61. 10.1161/HYPERTENSIONAHA.114.04012</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.114.04012</ArticleId><ArticleId IdType="pubmed">25399687</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciemins EL, Ritchey MD, Joshi VV, et al. . Application of a tool to identify undiagnosed hypertension - United States, 2016. MMWR Morb Mortal Wkly Rep 2018;67:798&#x2013;802. 10.15585/mmwr.mm6729a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6729a2</ArticleId><ArticleId IdType="pmc">PMC6065206</ArticleId><ArticleId IdType="pubmed">30048423</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazemian P, Shebl FM, McCann N, et al. . Evaluation of the cascade of diabetes care in the United States, 2005-2016. JAMA Intern Med 2019;179:1376&#x2013;85. 10.1001/jamainternmed.2019.2396</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2019.2396</ArticleId><ArticleId IdType="pmc">PMC6692836</ArticleId><ArticleId IdType="pubmed">31403657</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang M, Wang D, Coresh J, et al. . Trends in diabetes treatment and control in US. adults, 1999-2018. N Engl J Med 2021;384:2219&#x2013;28. 10.1056/NEJMsa2032271</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsa2032271</ArticleId><ArticleId IdType="pmc">PMC8385648</ArticleId><ArticleId IdType="pubmed">34107181</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood FA, Howard JP, Finegold JA, et al. . N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med 2020;383:2182&#x2013;4. 10.1056/NEJMc2031173</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2031173</ArticleId><ArticleId IdType="pubmed">33196154</ArticleId></ArticleIdList></Reference><Reference><Citation>Mach F, Baigent C, Catapano AL, et al. . 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111&#x2013;88. 10.1093/eurheartj/ehz455</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz455</ArticleId><ArticleId IdType="pubmed">31504418</ArticleId></ArticleIdList></Reference><Reference><Citation>Ference BA. Interpreting the clinical implications of drug-target Mendelian randomization studies. J Am Coll Cardiol 2022;80:663&#x2013;5. 10.1016/j.jacc.2022.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.06.007</ArticleId><ArticleId IdType="pubmed">35953132</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivakumaran J, Harvey P, Omar A, et al. . Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus. Lupus Sci Med 2021;8:e000448. 10.1136/lupus-2020-000448</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000448</ArticleId><ArticleId IdType="pmc">PMC8162102</ArticleId><ArticleId IdType="pubmed">34045359</ArticleId></ArticleIdList></Reference><Reference><Citation>Urowitz MB, Iba&#xf1;ez D, Su J, et al. . Modified Framingham risk factor score for systemic lupus erythematosus. J Rheumatol 2016;43:875&#x2013;9. 10.3899/jrheum.150983</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.150983</ArticleId><ArticleId IdType="pubmed">26879352</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, Singh M, Lele S, et al. . Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus. Lupus Sci Med 2022;9:e000564. 10.1136/lupus-2021-000564</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000564</ArticleId><ArticleId IdType="pmc">PMC8867320</ArticleId><ArticleId IdType="pubmed">35193947</ArticleId></ArticleIdList></Reference><Reference><Citation>Quevedo-Abeledo JC, Caceres L, Palazuelos C, et al. . QRISK3 relation to carotid plaque is higer than that of score in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2022;61:1408&#x2013;16. 10.1093/rheumatology/keab531</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab531</ArticleId><ArticleId IdType="pubmed">34240117</ArticleId></ArticleIdList></Reference><Reference><Citation>Sniderman AD, Thanassoulis G, Glavinovic T, et al. . Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol 2019;4:1287&#x2013;95. 10.1001/jamacardio.2019.3780</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2019.3780</ArticleId><ArticleId IdType="pmc">PMC7369156</ArticleId><ArticleId IdType="pubmed">31642874</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>